Gareth J. Morgan, MD, PhD

Articles

Dr. Morgan on the Differences in Low- and High-Risk Multiple Myeloma

August 2nd 2021

Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.

Dr. Morgan on Optimizing Treatment in Ultra High–Risk Multiple Myeloma

May 27th 2021

Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.

Dr. Morgan the Evolution of Treatment in Multiple Myeloma

June 11th 2020

Gareth J. Morgan, MD, PhD, discusses the evolution of treatment options in multiple myeloma.

Dr. Morgan on Treatment Selection in Multiple Myeloma

May 22nd 2020

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Dr. Morgan on Treatment Selection in Multiple Myeloma

May 21st 2020

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Dr. Morgan on Idecabtagene Vicleucel in Multiple Myeloma

April 17th 2020

Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Dr. Morgan on the Role of Venetoclax in Multiple Myeloma

April 14th 2020

Gareth J. Morgan, MD, PhD, discusses the role of venetoclax in treating patients with multiple myeloma.

Dr. Morgan on BCMA-Targeted ADCs in Multiple Myeloma

March 18th 2020

Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research, NYU Langone Health’s Perlmutter Cancer Center, discusses BCMA-targeted antibody-drug conjugates (ADCs) in multiple myeloma.